When Cancer Spreads to Only a Few Spots: What Doctors Are Learning About Rare Tumors

Scientists studying a rare type of cancer called neuroendocrine tumors, or NETs, have made an important discovery. In some patients, the cancer spreads to only a small number of spots — five or fewer. Doctors call this 'oligometastatic' disease, which means the cancer has traveled but hasn't spread widely. Researchers wanted to know if treating those few spots directly could help patients live longer. Their results were published in the British Journal of Cancer.

Neuroendocrine tumors are a type of cancer that grows in cells that produce hormones. They can start in the stomach, intestines, or pancreas. When cancer travels from where it started to other parts of the body, those new spots are called metastases. Most of the time, doctors treat widespread cancer with medicines that work throughout the whole body. But when there are only a few spots, some doctors wonder if targeting just those spots could work better.

In this study, researchers looked at 190 patients with NETs. About 55 of them had cancer that spread to five or fewer places, making them oligometastatic. The other patients had cancer in more than five spots, which is called polymetastatic disease. Researchers followed these patients for nearly 10 years on average. They wanted to compare how long each group of patients lived.

Surprisingly, patients with fewer metastases did not live significantly longer than those with more metastases. The median survival — the point at which half of patients were still alive — was about 117 months for the oligometastatic group and 100 months for the polymetastatic group. Scientists said that difference was not large enough to be considered meaningful. This challenged the idea that fewer cancer spots always leads to a much better outcome.

The study also found that nearly all oligometastatic patients had cancer that spread to just one organ. In 83% of cases, that organ was the liver. Spread to the bones or lungs only was very rare. This means that treatments aimed at the liver could be especially important for these patients. The liver is clearly the key battleground for this type of cancer spread.

Some patients received treatments aimed directly at their liver tumors. Options included surgery to remove tumors, radiofrequency ablation — which uses heat to destroy tumors — and embolization, which cuts off blood supply to tumors. Patients who got liver-directed treatment within 12 months lived a median of about 125 months. Those who did not get such treatment lived a median of about 100 months.

That two-year difference sounds important, but researchers said it was not statistically significant. That means the difference could have happened by chance due to the small number of patients. The study also had other limits, like differences between patients and the fact that it looked back at old records rather than testing a new treatment in a controlled way. Because of these issues, researchers could not say for sure that liver treatment was the reason some patients lived longer.

More than half of the oligometastatic patients eventually developed more widespread cancer over time. Scientists think this happens because tiny, hidden cancer cells — called micrometastases — may already be spreading even when scans look clear. New tools, like liquid biopsy, could one day help find these hidden cells by looking for cancer DNA in a patient's blood. For now, the best tool for detecting small NET spots early is a special scan called a Ga68-DOTATATE PET scan.

Researchers stressed that a large, carefully designed study is needed to give clearer answers. One trial already underway, called OligoRARE, is testing whether adding a focused radiation treatment helps patients with rare cancers that have spread to just a few spots. Results from that trial could change how doctors treat oligometastatic cancers in the future. Better evidence will help doctors make smarter decisions for each patient.

In the end, researchers said the number of cancer spots may matter less than whether all of those spots can be completely removed or destroyed. Because NETs grow slowly and hidden cancer cells may already exist, curing the disease with local treatment alone is very difficult. Doctors must carefully weigh all the facts when choosing the best plan for each patient. More research is the key to finding better answers.